SLXN

Silexion Therapeutics Corp. (SLXN) | Rumor.io

Silexion Therapeutics

SLXN

Attention (50-day avg)0%

Attention rank (50-day avg)#1,393

Bullish sentiment (50-day avg)80%

Price to earnings ratio0

Market capitalization1.4M

Earnings per share-19.9

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-11.9M

Social

What share of all stock conversation is about SLXN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.01	0.01% +0.01	0% +0	0% 0

Sep 29

Silexion Therapeutics (SLXN) has reported positive preclinical data on its KRAS cancer drug SIL204, showing it can ride naturally occurring lipoproteins into cells without the need for artificial nanoparticles.
The company has exercised 3.2 million Series E warrants for approximately $837,000 in gross proceeds, and has also issued 6.4 million new warrants (Series F and G) at the same strike price of $0.2603.
Silexion's stock price has risen significantly, with a 25% increase after the positive preclinical data was announced, and the company's market value is now approximately $2 million, with a share count of around 5.6 million.

Generated by AI

Sentiment

Of the messages about SLXN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	69.23% -29.09	85.71% +50	81.18% +20.07	79.66% +1.26
Bearish	30.77% +29.09	14.29% -50	18.82% -20.07	20.34% -1.26

Bullish· Sep 29

$SLXN has shown significant price appreciation in the past, with a 300% run, and has the potential for further growth.
The company has made significant progress in its Phase 2/3 clinical trial for SIL204, with regulatory clearance in Germany and Israel, and is expanding its target indications to colorectal and lung cancers.
With a strong team and promising results, $SLXN is expected to continue its upward trajectory, with some analysts predicting a price increase to $5-$10 per share.

Bearish· Sep 29

The company's premarket price rise was anticipated, and it has been subject to a "rug pull" strategy, where the price drops significantly after a short period of time.
The stock has been designed to have a slow and controlled price drop, making it difficult for investors to exit at a profit, and the author believes this is a deliberate tactic to manipulate the market.
The company's financial situation is dire, with only 1.2 months of cash left, and the author believes the stock will continue to decline, potentially below $0.30 within a few hours.

Generated by AI

Topics

Of the messages about SLXN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	60%	65.57%	60.42%	70.74%
Technical Analysis	20%	29.51%	36.46%	25.27%
Analysts	20%	4.92%	3.13%	3.46%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0.53%

Announcements· Sep 29

Silexion Therapeutics Ltd. reported positive preclinical findings for SIL204, its KRAS-targeting cancer therapy, which demonstrated robust, dose-dependent knockdown of mutant KRAS and uses the body's natural lipoproteins to enter cancer cells.
The company has advanced SIL204 into a Phase 2/3 clinical program for KRAS-driven pancreatic cancer, with potential expansion into colorectal and lung cancers, and has received regulatory clearance in Germany and Israel.
Silexion Therapeutics Ltd. exercised warrants for approximately $837,366 in gross proceeds, reducing the outstanding share count and increasing the company's capital, which will be used to fund its ongoing clinical trial.

Technical Analysis· May 20

The technical analysis suggests that $SLXN is trading in a support zone between $0.65 and $0.7, with a potential breakout above $0.68.
The chart is getting tight, with a cup and handle formation confirmed past resistance, and the RSI is bullish, indicating a potential breakout.
The breakout above $0.63 resistance line and the VWAP at $0.68 is contingent on strong volume, with a potential target of $0.90s.

Generated by AI

Community

Of the messages about SLXN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25.69%	33.08%	32.59%	18.47%
Newcomers	74.31%	66.92%	67.41%	81.53%

Regulars· Sep 29

The company has reported positive preclinical findings for its lead asset SIL204, demonstrating key mechanisms for endogenous systemic uptake in KRAS-driven cancers.
The company has raised $837,366 in gross proceeds through the immediate exercise of Series E warrants, with a reduced price of $0.2603 per share, and has an active Phase 2/3 clinical trial in locally advanced pancreatic cancer.
The company's stock has been experiencing volatility, with the price reaching as high as $0.50 and closing at $0.38, and the volume has been high, with 76M shares traded.

Newcomers· Sep 29

The newcomer is focused on the potential of Silexion Therapeutics Ltd.'s cancer-treatment preclinical data, which could lead to a significant increase in the stock price.
The newcomer is discussing the stock's overnight move and is hoping for a continued upward trend, with some even predicting a price of $1 or $2.
The newcomer is analyzing the company's recent press releases, highlighting the positive preclinical data on its KRAS cancer drug and the financing that will provide a significant influx of new warrants.

Generated by AI

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 26.8% to $0.32 during Tuesday's pre-market session. The company's market cap stands at $1.3 million. Summit Therapeutics (NASDAQ:SMMT) stock rose 16.34%

1d agobenzinga.com

Silexion Therapeutics Announces Exercise of Warrants

Cayman Islands, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced the entry into definitive agreements for the immediate exercise of certain outstanding series E warrants to purchase up to an aggregate of 3,216,928 of the Company’s ordinary shares originally issued in August 2026 having a reduced exercise price of

1d agofinance.yahoo.com

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

Silexion Therapeutics shares jump after hours on positive SIL204 preclinical findings for KRAS-driven cancers.

1d agoBenzinga

12 Health Care Stocks Moving In Monday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Chem

Gainers Silexion Therapeutics (NASDAQ:SLXN) shares rose 27.1% to $0.31 during Monday's after-market session. The market value of their outstanding shares is at $1.4 million. Chemomab Therapeutics (NASDAQ:CMMB)

1d agoBenzinga

Silexion reports preclinical data on SIL204 delivery mechanism

1d agoInvesting.com

Also Discussed

Investors talking about SLXN also mention

#	Name	Attention
1	MACA - Moringa Acquisition Corp	——
2	Banzai International Inc.BNZI	0%new
3	TCTM - TCTM Kids IT Education Inc.	——
4	GlucoTrack Inc.GCTK	0%0
5	ALUR - Allurion Technologies Inc.	——
6	HCW Biologics Inc.HCWB	0%0
7	Planet Image International Ltd. Class A Ordinary SharesYIBO	0%new
8	TMT Acquisition CorpTMTC	0%0
9	Alternus Clean Energy, Inc.ALCE	0%new
10	Insight Acquisition Corp.AMOD	0%0

Silexion Therapeutics Corp.

Healthcare
Biotechnology

Silexion Therapeutics Corp. is a clinical-stage biotechnology company focused on developing RNA interference (RNAi) therapies for KRAS-driven cancers. The company’s current work centers on treating difficult solid tumors, with an emphasis on pancreatic cancer and other malignancies linked to KRAS mutations. Its pipeline includes SIL204, a lead siRNA-based candidate designed to silence mutant KRAS using both local and systemic delivery approaches, as well as additional product programs under its LODER delivery platform. Silexion Therapeutics Corp. operates as an oncology-focused developer of targeted genetic therapies, combining drug design and delivery technology to address areas of unmet medical need in cancer treatment.

Website

Location

The Goldyne Savad Inst. of Gene Therapy

Jerusalem, 9112001

Israel

Social

What share of all stock conversation is about SLXN?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0.03% -0.01	0.01% +0.01	0% +0	0% 0

Sep 29

Silexion Therapeutics (SLXN) has reported positive preclinical data on its KRAS cancer drug SIL204, showing it can ride naturally occurring lipoproteins into cells without the need for artificial nanoparticles.
The company has exercised 3.2 million Series E warrants for approximately $837,000 in gross proceeds, and has also issued 6.4 million new warrants (Series F and G) at the same strike price of $0.2603.
Silexion's stock price has risen significantly, with a 25% increase after the positive preclinical data was announced, and the company's market value is now approximately $2 million, with a share count of around 5.6 million.

Generated by AI

Sentiment

Of the messages about SLXN that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	69.23% -29.09	85.71% +50	81.18% +20.07	79.66% +1.26
Bearish	30.77% +29.09	14.29% -50	18.82% -20.07	20.34% -1.26

Bullish· Sep 29

$SLXN has shown significant price appreciation in the past, with a 300% run, and has the potential for further growth.
The company has made significant progress in its Phase 2/3 clinical trial for SIL204, with regulatory clearance in Germany and Israel, and is expanding its target indications to colorectal and lung cancers.
With a strong team and promising results, $SLXN is expected to continue its upward trajectory, with some analysts predicting a price increase to $5-$10 per share.

Bearish· Sep 29

The company's premarket price rise was anticipated, and it has been subject to a "rug pull" strategy, where the price drops significantly after a short period of time.
The stock has been designed to have a slow and controlled price drop, making it difficult for investors to exit at a profit, and the author believes this is a deliberate tactic to manipulate the market.
The company's financial situation is dire, with only 1.2 months of cash left, and the author believes the stock will continue to decline, potentially below $0.30 within a few hours.

Generated by AI

Topics

Of the messages about SLXN that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	60%	65.57%	60.42%	70.74%
Technical Analysis	20%	29.51%	36.46%	25.27%
Analysts	20%	4.92%	3.13%	3.46%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	0%
Macro	0%	0%	0%	0.53%

Announcements· Sep 29

Silexion Therapeutics Ltd. reported positive preclinical findings for SIL204, its KRAS-targeting cancer therapy, which demonstrated robust, dose-dependent knockdown of mutant KRAS and uses the body's natural lipoproteins to enter cancer cells.
The company has advanced SIL204 into a Phase 2/3 clinical program for KRAS-driven pancreatic cancer, with potential expansion into colorectal and lung cancers, and has received regulatory clearance in Germany and Israel.
Silexion Therapeutics Ltd. exercised warrants for approximately $837,366 in gross proceeds, reducing the outstanding share count and increasing the company's capital, which will be used to fund its ongoing clinical trial.

Technical Analysis· May 20

The technical analysis suggests that $SLXN is trading in a support zone between $0.65 and $0.7, with a potential breakout above $0.68.
The chart is getting tight, with a cup and handle formation confirmed past resistance, and the RSI is bullish, indicating a potential breakout.
The breakout above $0.63 resistance line and the VWAP at $0.68 is contingent on strong volume, with a potential target of $0.90s.

Generated by AI

Community

Of the messages about SLXN, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	25.69%	33.08%	32.59%	18.47%
Newcomers	74.31%	66.92%	67.41%	81.53%

Regulars· Sep 29

The company has reported positive preclinical findings for its lead asset SIL204, demonstrating key mechanisms for endogenous systemic uptake in KRAS-driven cancers.
The company has raised $837,366 in gross proceeds through the immediate exercise of Series E warrants, with a reduced price of $0.2603 per share, and has an active Phase 2/3 clinical trial in locally advanced pancreatic cancer.
The company's stock has been experiencing volatility, with the price reaching as high as $0.50 and closing at $0.38, and the volume has been high, with 76M shares traded.

Newcomers· Sep 29

The newcomer is focused on the potential of Silexion Therapeutics Ltd.'s cancer-treatment preclinical data, which could lead to a significant increase in the stock price.
The newcomer is discussing the stock's overnight move and is hoping for a continued upward trend, with some even predicting a price of $1 or $2.
The newcomer is analyzing the company's recent press releases, highlighting the positive preclinical data on its KRAS cancer drug and the financing that will provide a significant influx of new warrants.

Generated by AI

Silexion Therapeutics

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Announcements· Sep 29

Technical Analysis· May 20

Regulars· Sep 29

Newcomers· Sep 29

Silexion raises $837,000 through warrant exercise at reduced price

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Summi

Silexion Therapeutics Announces Exercise of Warrants

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

12 Health Care Stocks Moving In Monday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Chem

Silexion reports preclinical data on SIL204 delivery mechanism

Also Discussed

Silexion Therapeutics Corp.

Company Information

Location

Silexion raises $837,000 through warrant exercise at reduced price

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Summi

Silexion Therapeutics Announces Exercise of Warrants

Silexion Therapeutics (SLXN) Stock Soars 61% After Hours: Here's What's Going On - Silexion Therapeutics

12 Health Care Stocks Moving In Monday's After-Market Session - Silexion Therapeutics (NASDAQ:SLXN), Chem

Silexion reports preclinical data on SIL204 delivery mechanism

Also Discussed

Social

Sep 29

Bullish· Sep 29

Bearish· Sep 29

Announcements· Sep 29

Technical Analysis· May 20

Regulars· Sep 29

Newcomers· Sep 29